The increased expression of G 1 cyclins has been associated with the many types of human tumors. In primary solid tumors however, the expression and activity of cyclin E2, the newest member of the G 1 cyclin family, is largely unknown. In this study we have analysed the expression of the E-type cyclins in primary solid tumors from breast, lung, uterus, ovary, colon, and rectal tissues. Relative gene expression was analysed by quantitative real-time reverse transcription polymerase chain reaction (Taqman). The levels of cyclin E1 and cyclin E2 were significantly elevated (23 vs 38%, respectively) in primary breast tumor samples relative to normal breast tissue controls. We also observed an inverse correlation between the expression of cyclin E1/ E2 and estrogen receptor in breast tumors. Our results demonstrate that the expression and associated catalytic activity for both cyclin E1 and cyclin E2 is elevated in primary breast tumors when compared to normal breast tissue. The increased level of cyclin E2 in breast tumors suggests that, similar to cyclin E1, it may contribute to the pathogenesis of breast cancer. Oncogene (2002) 21, 8529 -8534. doi:10.1038/sj.onc. 1206035
A number of studies have demonstrated a strong correlation between elevated levels of cyclin E1 and tumor progression and mortality (Muller-Tidow et al., 2001; Geng et al., 2001; Keyomarsi et al., 1994; GrayBablin et al., 1996; Loden et al., 1999; Nielson et al., 1996; Porter et al., 1997; Bortner and Rosenberg, 1997) . In addition, there is a correlation between elevated cyclin E1-Cdk2 kinase activity, increased phosphorylation of Rb, and increased rates of tumor cell proliferation in breast cancers (Loden et al., 1999) . However, the expression and activity of cyclin E2 in solid tumors is largely unknown. Our initial characterization of cyclin E2 expression in tumor derived cell lines and primary mouse embryonic fibroblasts lacking Rb demonstrated a strong association between elevated levels of cyclin E2 and the functional inactivation of Rb (Gudas et al., 1999; Geng et al., 2001) . We also demonstrated that cyclin E2 expression was elevated in lung tumor-derived cell lines in comparison to cell lines derived from normal lung tissue. Two recent studies evaluated the expression of cyclin E2 in early stage primary Non-Small Cell Lung Carcinoma (NSCLC) and in primary breast carcinoma (Muller-Tidow et al., 2001; Geng et al., 2001) . Interestingly, no significant elevation of cyclin E2 transcript levels was found in any of the lung tumors. In contrast, increased expression of cyclin E2 was observed in 25% of primary breast carcinomas.
To confirm and extend these recent observations we have analysed the expression of cyclin E2 in a variety of primary tumors and determined the catalytic activity associated with both cyclin E2 and cyclin E1 in primary breast tumors. Quantitative real-time RT -PCR (Taqman) analysis of primary tumor RNAs was used to determine the Relative Gene Expression (RGE) value for cyclin E1, cyclin E2, cyclin A, and Ki-67. A panel of primary tumor and matched normal adjacent tissue (NAT) RNAs were surveyed to determine the levels of cyclin E2 transcript. Ten matched tumor/NAT RNA samples for each of the following human tumor types were analysed for cdk2 associated cyclin expression: colorectal, lung, ovary/uterus, and breast. The cyclin E2 RGE level found in breast tumors had the greatest mean tumor/NAT ratio value (4.1) followed by lung (2.5), ovary/uterus (2.3), and colorectal tumors (1.2) (Figure 1a) . A tumor/NAT ratio value greater than one indicates increased level of transcript in tumor when compared to NAT. When comparing tumor to matched normal tissue, the overall expression levels and the tumor/NAT RGE ratio were greater for cyclin E1, cyclin A, and Ki-67 in lung, ovary/uterus and breast tumors when compared to cyclin E2 levels ( Figure 1b) .
Interestingly, in some tumor samples the expression of cyclin E1 was 15-to 70-fold higher than normal tissues, while induction of cyclin E2 was never greater than 10-fold. The median value in breast tumors was greater for cyclin E2 (4.11) when compared to cyclin E1 (3.71). These results indicate that even though cyclin E1 shows a greater range of expression, cyclin E2, on average, exhibits a higher level of expression in breast tumors. We had previously reported that cyclin E2 was elevated in cell lines derived from lung tumors when compared to normal bronchial epithelial cells (Gudas et al., 1999) . Our results indicate that cyclin E2 shows only a moderate overall induction (mean 2.5, maximum 5.9) in primary lung tumor samples while cyclin E1 shows a more dramatic induction (mean 6.61, maximum 19.8) (Figure 1b) . These results are in agreement with a recent report demonstrating that cyclin E1 levels are elevated in primary early stage NSCLC (Muller-Tidow et al., 2001) . To evaluate the possible transcriptional coupling between the genes analysed we calculated the correlation coefficient (R 2 ) and P-values (P) for the four tumor types using the tumor and NAT RPS9 normalized RGE values (n=80). This analysis revealed that only cyclin A/Ki-67 and cyclin E1/Ki-67 had R 2 values greater than 0.6 (P50.0001), indicating a moderate linear relationship ( Figure 1c ). The cyclin A and Ki-67 genes have previously been used as indicators of proliferation rate in primary tumors; therefore it is not surprising that this relationship exists (Miracco et al., 2000; Shaaban et al., 2002 , Dutta et al., 1995 . Interestingly, only the matched breast tumor and NAT dataset (n=20) demonstrated a significant linear correlation with cyclin E2 and the other gene pairs (cyclin E2/cyclin A: R 2 =0.911, cyclinE2/Ki-67: R 2 =0.848, and cyclin E1/ cyclin E2: R 2 =0.663) indicating that at least in breast tumors cyclin E2 expression was strongly coupled with proliferation ( Figure 1c) .
To confirm our RT -PCR (Taqman) results we examined the expression of cyclin E2 by Northern blot analysis in eight breast tumor samples with matched NAT. All of the breast tumor samples analysed contained detectable levels of cyclin E2, three of which exhibited high levels of cyclin E2 expression relative to controls ( Figure 2 ). Additionally, we performed in situ hybridization (ISH) analysis to examine the localization of cyclin E2 expression in a small sample set of primary tumors (lung, breast, colon, rectum, ovary, uterus, and prostate) with a cyclin E2 riboprobe (data not shown). We detected a strong hybridization to the cyclin E2 probe in two out of 15 of the tumor samples. The strongest cyclin E2 signal was detectable in a lung neuroendocrine carcinoma sample followed by a moderate signal in breast invasive ductal carcinoma sample. The signals were localized to the tumor cells with fairly uniform hybridization over most of the tumor mass with no detectable signal over the adjacent areas of stroma, necrosis, or lymphocyte infiltration.
We used RT -PCR (Taqman) analysis to demonstrate that the expression of cyclin E2 is increased by an average of threefold in human primary tumors derived from lung, ovary/uterus, and breast tissues when compared to matched NAT. By using linear correlation coefficient analysis we have shown that a statistically significant correlation exists between cyclin E1/E2 expression and cyclin A and Ki-67 expression in the breast tumor/NAT matched pairs. Although cyclin Figure 1 Cyclin E2 expression is elevated in primary breast and lung tumors. (a) Cyclin E2 expression levels were determined by quantitative real-time RT -PCR (Taqman) analysis of tumor and matched normal adjacent tissues (NAT) and normalized for relative gene expression (RGE). The RGE value was determined for each tumor normal pair based on the C t -value from a 5-point standard curve generated for each primer/probe set. The ribosomal protein S9 (RPS9) RNA was chosen as the 'housekeeping' gene for normalization because it consistently demonstrated the least mean deviation in cycle threshold (C t ) value between tumor and normal tissue RNA. Ten tumor/normal pair-matched patient samples from each of the following tumor types were analysed; colorectal, lung, ovary/uterus and breast. The box plot represents the Tumor/NAT induction values by five horizontal lines (10th, 25th, 50th or median, 75th, 90th-percentiles). The mean expression value is indicated by a black square. (b) Summary of Cdk2 associated cyclins and Ki-67 expression from the tumors analysed in a. Each tumor type is represented by 10 patient samples (Grade II -IV) and compared to normal adjacent tissue (NAT). Expression levels were calculated by normalizing the tumor and control (NAT) RGE ratios to the RPS9 housekeeping gene. (c) The linear correlation coefficients (R 2 ) and P-values were determined for each gene pair for the breast tumor and NAT RGE values E1 expression showed a similar correlation in other tumor types, this correlation was specific to breast tumors for cyclin E2 and was not observed to be statistically significant in the other tumor types analysed (data not shown). Since Ki-67 expression is indicative of proliferation these results demonstrate that the expression of cyclin E2 correlates with the proliferation status of breast tumors within this dataset.
Our initial screen indicated that the expression of cyclin E2 was frequently deregulated in primary breast tumors. Therefore, we increased the size and scope of the primary breast tumor samples to determine if relative differences exist between cyclin E2 versus cyclin E1 expression in breast cancer based on estrogen receptor status. Previous reports have demonstrated a correlation between elevated levels of cyclin E1 and estrogen receptor negative status (Nielsen et al., 1996; Keyomarsi et al., 1994) . We performed RT -PCR (Taqman) analysis of normal breast tissue RNA controls (n=17) and breast tumor RNAs that included ductal (n=16) and lobular (n=10) carcinomas. This dataset included both high grade (III/IV, poorly differentiated), medium grade (II, moderately differentiated) tumors, as well as tumors that had distant metastases (n=9). The patient samples were partitioned into ER-a high (greater than 0.1 RGE) and ERa low (less than 0.1 RGE) as determined by RT -PCR analysis (Figure 3) . We defined the overexpression (OE) cut-off value for tumors to be the mean normalized (control) expression of cyclin E1 and E2 in normal tissue plus four times the standard deviation. The majority (16 out of 17) of the control normal breast samples had RGE values that were higher than the cut-off RGE value for estrogen receptor positive status. Cyclin E2 was elevated in 17% (3 out of 18) of the ER-a (+) samples compared to 11% (2 out of 18) for cyclin E1. The population of ER-a (7) tumor samples represented 31% (8 out of 26) of the total number of breast tumor samples. Interestingly, cyclin E2 was increased in 88% (7 out of 8) and cyclin E1 in 50% (4 out of 8) of the ER-a (7) breast tumors (Figure 3) .
Overall the breast tumor samples exhibited elevated cyclin E2 RGE values (4OE cut-off) in 38% (10 out of 26) of the breast tumor samples as compared to 23% (6 out of 26) for cyclin E1 (Figure 3 ). Within the cyclin E2 dataset, six tumor samples expressed cyclin E2 transcript greater than 1.5-fold higher than the OE cutoff value. Breast tumor samples exhibited RGE values for cyclin E1 that were five times as likely to be within the expression range (mean+Std. Dev.) of normal breast tissue when compared to cyclin E2 RGE values. This indicates that, at least in the subset of breast tumor samples analysed, cyclin E2 is more likely to show modest transcriptional inductions detectable (Lower panel) RNA gels were stained with ethidium bromide (visible 28S and 18S bands) to assess loading efficiency above the normal mean. We performed regression analyses on the same set of both normal and breast tumor samples to evaluate the linearity of cyclin E expression (data not shown). This comparison revealed that 22% (6 out of 26) of tumors had high E2/low E1, 19% (5 out of 26) of tumors had high E2/high E1, and 4% (1 out of 26) of tumors had low E2/high E1. Elevated levels of cyclin E2 were detected in 55% (5 out of 9) of the tumor samples obtained from patients that developed distant metastases, while 33% (3 out of 9) of the same set of tumors showed high levels of both E-type cyclins.
Our data demonstrates that tumors lacking the estrogen receptor are statistically more likely to have elevated levels of both cyclin E1 and cyclin E2 than estrogen receptor positive breast tumors and normal breast tissue. Our analysis of estrogen receptor status strongly suggests that increased expression of cyclin E2 and E1 may lead to the uncoupling of the hormone response in breast tumor pathogenesis. By promoting S-phase entry without a need for hormone stimuli, cyclins and their CDK partners present an attractive target for treating breast tumors that are unresponsive to current anti-estrogen based therapies.
While the expression of cyclin E2 is elevated in tumors it is the associated kinase activity that is required for substrate phosphorylation and stimulation of cell cycle progression. To examine the kinase activity associated with cyclin E2 in primary breast and lung tumor tissue extracts we used a polyclonal antibody generated against an N-terminal human cyclin E2 peptide antigen to perform immunoprecipitation/kinase assays from primary tumors (Gudas et al., 1999) . We have demonstrated that this cyclin E2 antibody detects a *42 kD band in Saos-2 and Wi38va13 cell lysates that is competed by a cyclin E2 N-terminal peptide (data not shown). However, unlike these transformed cell lines, we have been unable to detect cyclin E2 protein in primary breast tumor tissue extracts by Western blot analysis. Nonetheless, we were able to readily detect Cdk2 bound to cyclin E2 and cyclin E2 associated kinase activity after immunoprecipitating cyclin E2 from a limited set of primary tumor extracts. Cyclin E2 and cyclin E1 immunoprecipitation analysis of primary tumor and normal tissue extracts from breast tissues demonstrated elevated levels of kinase activity in the tumor extracts when compared to normal tissue extracts (Figure 4b) . In primary breast tumors we detected elevated levels of cyclin E1 associated kinase activity in all of the tumors examined (mean induction 17.8), and elevated levels of cyclin E2 associated kinase activity in three out of four tumors (mean 7.9-fold) (Figure 4c ). To verify the total Cdk2 activity present and the background level of kinase activity, Cdk2 antibody and rabbit IgG were used as positive and negative controls, respectively (Figure 4a ). Cdk2 associated kinase activity in the MDA-MB-436 breast tumor cell line extracts were 10-fold higher than the cyclin E2 associated kinase activity and 374-fold higher than the IgG negative control (Figure 4a ). The elevated levels of kinase activity observed with Cdk2 immunoprecipitations was most likely due to the combined effect of measuring kinase activity from cyclin A, cyclin E1 and cyclin E2-Cdk2 complexes. Cdk2 Western blot analysis of the anti-cyclin E immunoprecipitations revealed that every tumor sample contained Cdk2 protein bound to cyclin E (Figure 4b ). These data suggest that, in comparison to normal breast tissue, high-grade invasive breast ductal carcinomas have elevated levels of both cyclin E1 and cyclin E2 associated kinase activity.
The co-immunoprecipitation results suggest that either lower levels of cyclin E2 protein compared to cyclin E1 are present in tumor samples or that the efficiency of immunoprecipitations is lower with cyclin E2 antibody as compared to cyclin E1 antibody. Interestingly, we have demonstrated that p27
Kip1 was bound to cyclin E2-Cdk2 and not cyclin E1-Cdk2 complexes in several of the primary breast tumor extracts (data not shown). By binding and sequestering p27 Kip1 , cyclin E2-Cdk2 complexes may be acting as a p27
Kip1 sink providing a possible explanation for the elevated levels of cyclin E1-associated kinase activity in breast tumors. Additionally, titration experiments on tumor derived cell lines with myc-tagged cyclin E1 and E2 plasmids established that five times more cyclin E2 plasmid DNA was required to achieve the equivalent relative intensity signal of cyclin E1 protein using a myc-epitope specific antibody for western analysis (data not shown). Also co-transfections with Cdk2 or p27
Kip1 increases the levels of detectable cyclin E2 protein implying that complex formation has a stabilizing effect on cyclin E2 protein (Payton and Coats, 2002; Gudas et al., 1999; Zariwala et al., 1998) . Our results indicate that cyclin E2 appears to be a highly labile protein that is expressed at very low protein levels in primary breast tumor samples. Further studies are required to determine which pathways may be involved in regulating cyclin E2 protein turnover.
Collectively, our data provides the first evidence that cyclin E2-associated kinase activity is increased in primary breast tumors when compared to normal breast tissue. The elevated kinase activity is likely due to multiple factors including decreased levels of Cdk2 inhibitors (i.e. p27
Kip1 and p21 Cip1 ), increased expression of cyclin E2 and Cdk2 protein, and increased proliferation rates associated with breast epithelial cell transformation. Interestingly, both cyclin E1 and cyclin E2-associated kinase activity is elevated in breast tumors, suggesting that both complexes may have important unique or overlapping substrates whose phosphorylation is required for cell cycle progression. Future studies will need to be performed to determine if the increased expression and associated kinase activity for cyclin E2 plays a role in the pathogenesis of breast cancer. Immunoprecipitation of protein lysates from breast tumor and normal breast tissue with cyclin E1 and cyclin E2 specific antibodies detected elevated levels of cyclin E associated Histone H1 kinase activity in tumors (T 1 -4 ) relative to the normal breast tissue controls (N 1 -3 ) . (Lower panel) Western blot analysis of the immunoprecipitated cyclin E complexes detected associated Cdk2 protein in both the tumor and normal extracts. Extracts from a proliferating breast tumor derived cell line (MDA-MB-436) were used as a positive control (C) for both cyclin E2 and cyclin E1. (c) Mean Histone H1 kinase activities from a PhosphoImager ImageQuant scan of the data for cyclin E1 and cyclin E2 immunoprecipitations/kinase assays from tumor extracts versus normal tissue extracts. Cyclin E1 had a mean fold induction in tumors of 17.8, while cyclin E2 had a mean fold induction of 7.9
